Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients with BRCA 1/2 - Mutated Cancer or PARP Sensitive Tumor Types

Veliparib (ABT-888) is a novel oral poly-ADP-ribose polymerase (PARP) inhibitor that is being developed for the treatment of hematologic malignancies and solid tumors. Although the pharmacokinetics of veliparib has been studied in combination with cytotoxic agents, limited information exists regardi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Pharmacol
Main Authors: Niu, Jing, Scheuerell, Christie, Mehrotra, Shailly, Karan, Sharon, Puhalla, Shannon, Kiesel, Brian F., Ji, Jiuping, Chu, Edward, Gopalakrishnan, Mathangi, Ivaturi, Vijay, Gobburu, Jogarao, Beumer, Jan H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5503785/
https://ncbi.nlm.nih.gov/pubmed/28387939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.892
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados